Navigation Links
New drug to multiple sclerosis symptoms

A new drug AVP-923 is all set to provide relief to people suffering from the dreaded disease of multiple// sclerosis, said the researchers from University of Vermont College of Medicine, US.

Multiple sclerosis is a chronic neurological disease of the central nervous system. The disease affects the brain and spinal cord and medication till date had only been able to treat the problem symptomatically. One of the symptoms of this disease is called pseudobulbar affect is often characterized by episodes of laughter and crying in inappropriate situations. The outbursts are often spontaneous and the patients may have very little control over the expressions.

The new drug will be helping the patients to control much of their inappropriate emotional outbursts. The patients who were given the drug in the clinical trial had also reported of improvement in their quality of life, interpersonal relationships and physical comfort and pain. One of the side effects of the drug was reported to be spells of dizziness.

This is the first drug designed to specifically treat the condition of pseudobulbar affect in patients with multiple sclerosis. The results of the study was presented at the American Academy of Neurology 57th Annual Meeting, held on April 9-16.

Reference: American Academy of Neurology 57th Annual Meeting, Press Release
'"/>




Page: 1

Related medicine news :

1. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
2. Associated therapy for multiple myeloma
3. Latest drug shows promise in multiple myeloma
4. Vitamin D to reduce multiple sclerosis
5. Smoking may affect multiple sclerosis
6. Low immunity in people with multiple sclerosis may be genetical
7. Thalidomide is the new approved drug for treating multiple cancers
8. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
9. Calcium-blocker delays atherosclerosis than beta-blockers
10. Adult stem cells in treatment for Multiple sclerosis (MS)
11. Vitamin D to reduce multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... , ... December 08, 2016 , ... Premier Fitness Camp ... FIT , the ultimate weight loss and wellness program, at their world headquarters of ... to provide immediate and long-term results to anyone seeking weight loss, personal development, a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that it had joined the Pharmaceutical Supply Chain ... organization to unite pharmaceutical and healthcare companies that share a vision of better, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... California Senate Bill ... payments per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical ... Institute (WCRI) . , According to the study, medical payments per claim in California ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX ... Nationwide Children,s Hospital signed a membership ... accelerate the development of new cures. ... representing over 57 million patients globally, biopharmaceutical companies ... together to improve protocol design, site selection, patient ...
(Date:12/8/2016)... LAVAL, Quebec , Dec. 8, 2016 /PRNewswire/ ... and TSX: VRX) ("Valeant") today announced positive ... vehicle-controlled clinical study to assess the safety and ... in the treatment of plaque psoriasis. ... adult subjects with moderate to severe psoriasis, IDP-118 ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, LLC ... obtained proof-of-mechanism for neflamapimod (previously code named VX-745), ... 2a clinical trials that demonstrated significant Alzheimer,s disease ... (12-week treatment) and Study 303 (6-week treatment) are ... in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: